Portal de Periódicos da CAPES

Prognostic Value of Serum β-2 Microglobulin in Low-Grade Lymphoma

1991; American College of Physicians; Volume: 114; Issue: 10 Linguagem: Inglês

10.7326/0003-4819-114-10-855

1539-3704

Patrick P. Litam, F Swan, Fernando Cabanillas, Susan L. Tucker, Peter McLaughlin, Fredrick B. Hagemeister, Maria Alma Rodriguez, William S. Velasquez,

Acute Lymphoblastic Leukemia research

Article15 May 1991Prognostic Value of Serum β-2 Microglobulin in Low-Grade LymphomaPatrick Litam, MD, Forrest Swan, MD, Fernando Cabanillas, MD, Susan L. Tucker, PhD, Peter McLaughlin, MD, Fredrick B. Hagemeister, MD, Maria A. Rodriguez, MD, William S. Velasquez, MDPatrick Litam, MD, Forrest Swan, MD, Fernando Cabanillas, MD, Susan L. Tucker, PhD, Peter McLaughlin, MD, Fredrick B. Hagemeister, MD, Maria A. Rodriguez, MD, William S. Velasquez, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-114-10-855 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptObjective: To evaluate serum beta-2 microglobulin (β-2M) and other prognostic indicators in previously untreated low-grade lymphoma.Design: Cohort study of 80 patients with uniformly treated low-grade lymphoma, followed for a median of 21 months. These 80 patients, all of whom had serum /3-2M drawn within 2 weeks before starting therapy, were derived from a cohort of 119 previously untreated patients entered into one of three clinical trials.Setting: Tertiary referral cancer center.Patients: Eighty previously untreated stage I to IV patients (mean age, 55 years).Intervention: Treatment was given according to Ann Arbor stage: Patients in stage IV were treated with CHOP-bleomycin and maintained on interferon therapy; those in stage III received CHOP-bleomycin and radiotherapy; and those in stages I and II received COP-bleomycin and radiotherapy.Measurements: Outcome was determined by assessing complete remission rate and time to treatment failure. Univariate and multivariate analyses were used.Results: The complete remission rate for patients with a β-2M level of 3. 0 mg/L or greater was 36% compared with 71% for those with a level of less than 3.0 mg/L. Using multivariate analysis that tested /3-2M as a continuous variable, it was selected as the most significant factor for complete response. The adjusted odds ratio was 0.285 (95% CI, 0.101 to 0.809). The Ann Arbor stage had marginal significance (adjusted odds ratio, 0.435; CI, 0.150 to 1.263). For time to treatment failure, β-2M was the only variable retained in the multivariate model. At 42 months, no patient with a β-2M level of 3.0 mg/L or greater was projected to be in remission as compared with 85% of patients with a β-2M level of less than 3.0 mg/L.Conclusions:The serum β-2M level is a good predictor of complete response and time to treatment failure. A larger number of patients should be studied to clarify the role of other potentially independent variables such as stage and age....References1. Peterson P, Cunningham B, Berggard I, and Edelman G. 2-Microglobulin-a free immunoglobulin domain. Proc Natl Acad Sci USA. 1972;69:1697-701. CrossrefMedlineGoogle Scholar2. Berggard I and Beam A. Isolation and properties of a low molecular weight beta-2-globin occurring in human biological fluids. J Biol Chem. 1968;243:4095-103. CrossrefMedlineGoogle Scholar3. Grey H, Kubo R, and Colon S. The small subunit of HLA antigens is beta 2-microglobulin. J Exp Med. 1973;138:1608-12. CrossrefMedlineGoogle Scholar4. Cresswell P, Springer T, Strominger J, Turner M, Grey H, and Kubo R. Immunological identity of a small subunit of HLA antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci USA. 1974;71:2123-7. CrossrefMedlineGoogle Scholar5. Parham P, Barnstable C, and Bodmer W. Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C antigens. J Immunol. 1979;123:342-9. CrossrefMedlineGoogle Scholar6. Evrin P and Wibell L. Serum 2-microglobulin in various disorders. Clin Chem Acta. 1973;43:183-6. CrossrefMedlineGoogle Scholar7. Shuster J, Gold P, and Poulik M. Beta 2-microglobulin levels in cancerous and other diseases states. Clin Chim Acta. 1976;67:307-13. CrossrefMedlineGoogle Scholar8. Alexanian R, Barlogie B, and Fritsche H. Beta 2 microglobulin in multiple myeloma. Am J Hematol. 1985;20:345-51. CrossrefMedlineGoogle Scholar9. Bataille R, Durie B, and Grenier J. Serum beta-2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging. Br J Haematol. 1983;55:439-47. CrossrefMedlineGoogle Scholar10. Child J, Spati B, and Illingworth S. Serum beta 2 microglobulin and C-reactive protein in the monitoring of lymphomas: findings in a multicenter study and experience in selected patients. Cancer. 1980;45:318-26. CrossrefMedlineGoogle Scholar11. Hagberg H, Killander A, and Simonsson B. Serum beta 2-microglobulin in malignant lymphoma. Cancer. 1983;51:2220-5. CrossrefMedlineGoogle Scholar12. Swan F, Velasquez W, and Tucker S. A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels. J Clin Oncol. 1989;7:1518-27. CrossrefMedlineGoogle Scholar13. National Cancer Institute sponsored study of classification of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112-35. CrossrefMedlineGoogle Scholar14. Carbone P, Kaplan H, Musshoff K, Smithers D, and Tubiane M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res. 1971;31:1860-1. MedlineGoogle Scholar15. McLaughlin P, Fuller L, and Hagemeister F. Stage III low-grade lymphomas (LGL): a prospective trial of combination chemotherapy (CT) and radiotherapy (XT). [Abstract]. Proceedings of the 4th International Conference of Malignant Lymphoma. Lugano, Switzerland, June 1990. Google Scholar16. McLaughlin P, Fuller L, and Velasquez W. Stage HI follicular lymphoma: durable remissions with a combined chemotherapy-radiotherapy regimen. J Clin Oncol. 1987;5:867-74. CrossrefMedlineGoogle Scholar17. Dixon D, McLaughlin P, and Hagemeister F. Reporting outcomes in Hodgkin's disease and lymphoma. J Clin Oncol. 1987;5: 1670-2. CrossrefMedlineGoogle Scholar18. Kaplan E and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81. CrossrefGoogle Scholar19. Gehan E. Generalized Wilcoxon test for comparing arbitrarily singly censored samples. Biometrika. 1965;52:203-23. CrossrefMedlineGoogle Scholar20. Cox D. Regression models and life tables. J Stat Soc. (Ser B). 1972;34:187-202. Google Scholar21. Jagannath S, Velasquez W, and Tucker S. Tumor burden assessment and its implication for a prognostic model in advanced diffuse large-cell lymphoma. J Clin Oncol. 1986;4:859-65. CrossrefMedlineGoogle Scholar22. Ferraris A, Giuntini P, and Gaetani G. Serum lactic dehydrogenase as a prognostic tool for non-Hodgkin lymphomas. Blood. 1979;54: 928-32. CrossrefMedlineGoogle Scholar23. Amlot P and Adinolfi M. Serum beta 2 microglobulin and its prognostic value in lymphomas. Eur J Cancer. 1979;15:791-6. CrossrefMedlineGoogle Scholar24. Legros M, Fernere J, and Bignon Y. Beta-2M: a good prognostic indicator in non-Hodgkin's lymphoma [Abstract], Proceedings of the American Society of Clinical Oncology. 1987;6:748. Google Scholar25. Nilsson K, Evrin P, and Welsh K. Production of beta 2-microglobulin by normal and malignant human cell lines and peripheral lymphocytes. Transpl Rev. 1974;21:53-84. MedlineGoogle Scholar26. Schneider R, Seibert K, and Passe S. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Cancer. 1980; 46:139-43. CrossrefMedlineGoogle Scholar27. Vezzoni M, Luchini R, Giardini R, Raineri M, Murone M, and Vezzoni P. Lactate dehydrogenase levels in cellular extracts of human malignant lymphoma. Tumori. 1983;69:279-82. CrossrefMedlineGoogle Scholar28. Gospodarowicz M, Bush R, Brown T, and Chua T. Prognostic factors in nodular lymphomas: a multivariate analysis on the Princess Margaret Hospital experience. Int J Radiat Oncol Biol Phys. 1984;10:489-97. CrossrefMedlineGoogle Scholar29. Rudders R, Kaddis M, DeLeIUs R, and Casey H. Nodular non-Hodgkin's lymphoma (NHL): factors influencing prognosis and indications for aggressive treatment. Cancer. 1979;43:1643-51. CrossrefMedlineGoogle Scholar30. Swan F, Ordonez N, and Manning J. Beta 2 microglobulin cell surface expression as an indicator of resistance in lymphoma and its relation to the serum level [Abstract]. Blood. 1988;72:258a. Google Scholar31. Bodmer W. HLA structure and function: a contemporary view. Tissue Antigens. 1981;17:9-20. CrossrefMedlineGoogle Scholar32. Bach F and Rood J. The major histocompatibility complex-genetics and biology. N Engl J Med. 1976;295:872-7. CrossrefMedlineGoogle Scholar33. Bach F and Rood J. The major histocompatibility complex: genetics and biology. N Engl J Med. 1976;295:927-36. CrossrefMedlineGoogle Scholar34. Male D. Histocompatibility loci and transplantation. In: Male DK, ed. Immunology. CV Mosby Company; 1986:57-72. Google Scholar35. Zinkernagel R and Doherty D. MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness. Adv Immunol. 1979;27:151-77. Google Scholar36. Hui K, Grosveld F, and Festenstein H. Rejection of transplantable AKR leukaemia cells following MHC DNA-mediated cell transformation. Nature. 1984;311:750-2. CrossrefMedlineGoogle Scholar37. Moller P, Herrmann B, Moldenhauer G, and Momburg F. Defective expression of MHC class I antigens is frequent in B-cell lymphomas of high-grade malignancy. Int J Cancer. 1987;40:32-9. CrossrefMedlineGoogle Scholar38. Moller P, Lammler B, Herrmann B, Otto H, Moldenhauer G, and Momburg F The primary mediastinal clear cell lymphoma of B-cell type has variable defects in MHC antigen expressions. Immunology. 1986;59:411-7. MedlineGoogle Scholar39. Arce-Gomez B, Jones E, Barnstable C, Solomon E, and Bodmer W. The genetic control of HLA-A and B antigens in somatic cell hybrids: requirement for beta 2 microglobulin. Tissue Antigens. 1978;11:96-112. CrossrefMedlineGoogle Scholar40. Trowsdale J, Travers P, Bodmer W, and Patillo R. Expression of HLA-A, -B, and -C and beta 2-microglobulin antigens in human choriocarcinoma cell lines. J Exp Med. 1980;152:115-79. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: Patrick Litam, MD; Forrest Swan, MD; Fernando Cabanillas, MD; Susan L. Tucker, PhD; Peter McLaughlin, MD; Fredrick B. Hagemeister, MD; Maria A. Rodriguez, MD; William S. Velasquez, MDFrom the University of Texas M. D. Anderson Cancer Center, Houston, Texas. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byRisk factors for POD24 in patients with previously untreated follicular lymphoma: a systematic review and meta-analysisCirculating microRNAs Correlate with Multiple Myeloma and Skeletal Osteolytic LesionsSerum beta-2 microglobulin analysis in patients with oral squamous cell carcinomaPretransplant serum beta‐2 microglobulin level is a potential novel prognostic marker of overall survival after allogeneic hematopoietic cell transplantation – a retrospective observational studyA simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapyNon‐ H odgkin's Malignant LymphomaSerum beta-2 microglobulin in malignant lymphomas: an old but powerful prognostic factorA Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—TositumomabLow expression of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin-related protein in non-Hodgkin lymphoma and significant correlations with lactic acid dehydrogenase and β2-microglobulinSurvival in patients with oral and maxillofacial diffuse large B-cell lymphomaBeta-2 microglobulin as an immunological marker to assess the progression of human immunodeficiency virus infected patients on highly active antiretroviral therapyPrognostic Factors in Follicular LymphomaPrognostic analysis and a new risk model for Hodgkin lymphoma in JapanSurvival and Years of Life Lost in Different Age Cohorts of Patients With Multiple MyelomaPrognostic tools in follicular lymphomasFollicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor ProjectLevels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemiaThe Prognostic Significance of Serum β2 Microglobulin Levels in Acute Myeloid Leukemia and Prognostic Scores Predicting Survival: Analysis of 1,180 PatientsDiffuse Large B-Cell LymphomaLymphomasClinical and molecular prognostic factors in follicular lymphomaUrinary pseudouridine in patients with lymphoma: Comparison with other clinical parametersPrognostic significance of PU.1 in follicular lymphomaPrognosis of follicular lymphomasFollicular LymphomaHigh Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and CytarabinePrognostic indexes in follicular lymphoma: a comparison of different prognostic systemsPrognosis of Follicular LymphomasPredictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progressionExpression of bcl-6 and CD10 Protein Is Associated With Longer Overall Survival and Time to Treatment Failure in Follicular LymphomaContribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)Long-Term Follow-Up of a Prospective Study of Combined Modality Therapy for Stage I–II Indolent Non-Hodgkin's LymphomaNon-Hodgkin's LymphomaAn elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin diseaseClinicopathologic Correlations of Genomic Gains and Losses in Follicular LymphomaSurvival after progression in patients with follicular lymphoma: analysis of prognostic factorsEfficacy of Fludarabine/Mitoxantrone/Dexamethasone Alternating with CHOP in Bulky Follicular Non-Hodgkin's LymphomaHigh-dose therapy for indolent lymphomaβ 2 microglobulin serum levels and prediction of survival in AL amyloidosisSerum nm23-H1 protein as a prognostic factor for indolent non-Hodgkin's lymphomaElevated serum levels of soluble interleukin-2 receptor, neopterin and β-2-microglobulin in idiopathic dilated cardiomyopathy: relation to disease severity and autoimmune pathogenesisCost-Effectiveness of Interferon Alfa-2b Added to Chemotherapy for High-Tumor-Burden Follicular Non-Hodgkin's LymphomaA new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levelsAllogeneic hematopoietic transplantation for chronic lymphocytic leukemia and lymphoma: Potential for nonablative preparative regimensLow-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients—A Study of the Groupe d'Etude des Lymphomes de l'AdulteSerum beta-2-microglobulin, TNF-α and interleukins in myeloproliferative disordersThe biological Markers of Non-Hodgkin'S Lymphomas: Their Role in Diagnosis, Prognostic Assessment and Therapeutic StrategyPrognostic factor analysis in mycosis fungoides/Sézary syndromeTumor Markers in OncologyInroads in the Therapy of Indolent Lymphomas: Exploiting Biological InsightsCorrelation and Prognostic Value of Serum Soluble ICAM-1, Beta-2 Microglobulin, and IL-2αR Levels in Non-Hodgkin's LymphomaHigh Serum Interleukin-6 Levels Correlate with a Shorter Failure-Free Survival in Indolent LymphomaLow-grade non-Hodgkin's lymphoma - Biology and therapeutic approachesFollicular Lymphomas: Morphology, Prognostic Factors and TreatmentEffects of Alpha-Interferon on Serum Beta-2-MicroglobulinLow-grade lymphomas: new entities and treatment conceptsNon-Hodgkin LymphomasPrognostic Factors in Aggressive Non-Hodgkin's LymphomaLABORATORY CHARACTERIZATION OF MALIGNANCIES OF THE IMMUNE SYSTEMLow-grade lymphoma 1993: State of the artLow-Grade Lymphoma: Clinical and Prognostic Studies in a Series of 143 Patients from a Single InstitutionNon-Hodgkin's Lymphoma in the Older Person: A ReviewElevated circulating levels of beta 2-microglobulin in patients with idiopathic dilated cardiomyopathySerum Tumor Markers in Non-Hodgkin's Lymphomas and Chronic Lymphocytic LeukemiaValue of Serum Beta 2 Microglobulin as an Indicator of Early Relapse in Diffuse Large Cell LymphomaCan we Identify Patients with Low Grade Lymphoma for Frontline ABMT?Prognostic significance of elevated serum β2-microglobulin levels in adult acute lymphocytic leukemiaImmune and hormonal changes in early-stage chronic lymphocytic leukemia patientsRespiratory diseasesBeta 2 Microglobulin Level as an Indicator of Prognosis in Diffuse Large Cell LymphomaClinical use of tumor markers in oncologyHow should prognostic factors influence therapy in follicular lymphomas?The Indolent B-Cell Lymphomas 15 May 1991Volume 114, Issue 10 Page: 855-860 Keywords Adjusted odds ratio Clinical trials Cohort studies Hospital medicine Interferons Lymphoma Multivariate analysis ePublished: 1 December 2008 Issue Published: 15 May 1991 Copyright & Permissions© 1991 American College of PhysiciansPDF downloadLoading ...